Sanofi's 1st-qtr 2018 hit by falling sales

27 April 2018

Despite being upbeat about future growth, the shares of French pharma major Sanofi (Euronext: SAN) fell 1.84% to 65.09 euros by mid-morning, after the company released first-quarter 2018 financial results that disappointed.

In the first quarter, Sanofi generated net sales of 7,898 million euros ($9.67 billion), a decrease of 8.7% (down 0.4% at CER). The Sanofi Genzyme unit’s sales grew strongly, up 16.2%, driven by contribution from the new immunology franchise

Net income, as reported was 1,016 million euros, down 82.2%, or 0.81 euros per share. That compared to expected sales of 8 billion euros and income of 1.4 billion euros in a poll of economists by Reuters. Business net income came in at 1,598 million euros, down 10.7%, and EPS was 1.28 euros, down 9.9%.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK